AlphAIAlphAI — Financial news for AI agents
rttnews.comAUG 74 min read$CLLS

Cellectis Posts Q2 2026 Results, Highlights Progress Across Allogenic CAR-T Pipeline

Cellectis (CLLS) reported Q2 2026 cash, cash equivalents and fixed-term deposits of $169M as of June 30, 2026, versus $145M in Q2 2025, citing runway into Q4 2027. At EHA 2026, lasme-cel in BALLI-01 moved to pivotal Phase 2 after FDA RMAT (June 2026), with ORR 67% and CR 56% in Phase 1. Eti-cel in NATHALI-01 showed ORR 46% and CR 31%.

Original reporting
rttnews.com
Published Aug 7, 2026, 9:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 9:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$CLLS
Bullish
medium confidence
Mentioned
$CLLS
Relevance
7/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$CLLSBullishMed
01

Why it matters

The combination of stronger liquidity (cash into Q4 2027) and a regulatory milestone (RMAT designation) for lasme-cel, alongside reported response rates, can shift expectations for trial progression and future financing needs.

02

Market read

Traders may reprice Cellectis based on RMAT-linked pivotal progression for lasme-cel and the stated interim Phase 2 analysis window in Q4 2026, supported by improved cash runway.

03

What to watch

Cash runway is extended, but the article does not quantify burn rate, dilution risk, or manufacturing/commercial readiness, which can cap upside despite RMAT progress.

Relevance 7/10Novelty 6/10Timing: today, pre-market/early session coverage of Q2 results and EHA pipeline updates

Background

Cellectis is a clinical-stage biotech focused on gene-edited allogeneic CAR-T therapies, with updates presented at the EHA 2026 Annual Congress.

Company-level read

Ticker impact

$CLLSBullishMedium confidence
Context

Cellectis reported Q2 2026 cash of $169M and advanced lasme-cel to pivotal Phase 2 after FDA RMAT designation in June 2026.

Expected impact

Moderately positive bias, with volatility likely around Q4 2026 interim Phase 2 expectations.

Evidence & confidence

The article adds specific, decision-relevant clinical/regulatory milestones (RMAT in June 2026, pivotal Phase 2, interim analysis expected Q4 2026) plus liquidity runway into Q4 2027, which can support valuation and trading positioning.

Market effects

Sector

Supports sentiment for allogeneic CAR-T development, especially CD22-positive B-ALL programs with RMAT-linked momentum.

Regional

Limited direct regional impact; EHA congress context may influence European biotech sentiment.

Global

Moderate global read-through for gene-edited cell therapy investors tracking RMAT and pivotal Phase 2 transitions.

Counterpoint

What could challenge this read

Efficacy metrics are encouraging but still early-stage for pivotal Phase 2; interim Phase 2 timing in Q4 2026 may be too far to re-rate immediately.

Key entities

  • company
    Cellectis

    Reported Q2 2026 liquidity and provided clinical pipeline updates for lasme-cel and eti-cel at EHA 2026.

  • program
    Lasme-cel

    BALLI-01 relapsed/refractory B-ALL program moved into pivotal Phase 2 after FDA RMAT designation in June 2026.

  • program
    Eti-cel

    NATHALI-01 relapsed/refractory non-Hodgkin lymphoma program remains in Phase 1 with full dataset expected in Q4 2026.

Read at source← All news

Related articles

SEP 16
$CLLSHigh

Cellectis stock tumbles after Barclays double downgrade

Cellectis SA (CLLS) shares dropped 14.6% after Barclays downgraded the stock to Underweight, cutting its price target to $1.30 from $9.00. Analyst Lukas Shumway cited lack of conviction in Cellectis' new programs, assigning negative net present values to .HEAL-101 and .HEAL-201. The valuation model now includes $2 each for Royalties and Milestones, -$1 for Debt, and $5 for Cash, assuming a capital raise in late 2027.

investing.com2 min
JUN 9
$CLLSMedAI 9/10

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL

Cellectis said the FDA granted RMAT designation to lasme-cel, its CD22-targeting allogeneic CAR-T candidate, for relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). The company cited Phase 1 BALLI-01 data for efficacy and a manageable safety profile. Final Phase 1 results are scheduled for presentation at EHA on June 13; BALLI-01 Phase 2 enrollment is open.

manilatimes.net4 min
SEP 17
$BWINMed

Michael Dell Just Made a $7.7 Billion Bet on This Insurance Stock

Michael Dell is acquiring Baldwin & Co. (BWIN) for $7.7B. Baldwin reported Q2 revenue of $492.9M (+30% YoY), adjusted net income of $68.5M, and adjusted EBITDA of $116.7M (+37%). Management guided Q3 revenue to $485M-$495M and full-year revenue to $2.01B-$2.05B. Analysts have mixed targets, with a consensus 'Moderate Buy' and average target of $33.

yahoo.com2 min
SEP 17
$AMZNMedAI 8/10

Should You Buy Amazon Stock For The Demand AWS Cannot Yet Serve?

Amazon.com (AMZN) stock is down 13% from its 52-week high, despite AWS's 36.7% YOY revenue growth in Q2 2026. AWS's backlog of committed contracts reached $496 billion, with demand outpacing capacity. AWS's operating margin improved 520 basis points YOY, excluding energy contract gains. Management attributes growth to AI workloads and efficient capacity use.

yahoo.com3 min
SEP 17
$ASMLMedAI 8/10

Weakness Is an Opportunity for Long-Term ASML Stock Investors

ASML's High-NA technology is gaining traction among chipmakers like Samsung, Intel, and TSMC, crucial for its long-term outlook. Q2 earnings beat estimates with €7.59 EPS and €9.33B revenue. ASML raised full-year 2026 sales guidance to €43B-€45B. Analysts have a consensus 'Hold' rating, with a mean price target of $2,350.75, implying 56% upside.

yahoo.com3 min
SEP 17
$LENMedAI 8/10

Lennar (LEN) Q3 2026 Earnings Call Transcript

Lennar (LEN) reported Q3 2026 net earnings of $284M, down 52% YoY, with GAAP EPS at $1.19. Revenues were $8B, driven by home sales. New orders and deliveries decreased due to affordability constraints. The company revised full-year delivery guidance to 80K-81K homes. Management cited higher interest rates and labor pressures as key challenges.

aol.com3 min